<DOC>
	<DOCNO>NCT02254850</DOCNO>
	<brief_summary>The purpose study characterize action mesoglycan vascular endothelium non-invasive assessment vascular reactivity humeral artery compare effect mesoglycan Flow Mediated Dilatation ( FMD ) humeral artery group patient metabolic syndrome assume placebo group patient metabolic syndrome assume mesoglycan ; firstly administration drug/placebo intramuscularly , , study medium-term oral intake drug/placebo . The selection patient metabolic syndrome related fact syndrome associate alteration endothelial function high incidence cardiovascular event . So condition offer opportunity explore hypothesis mesoglycan may favorable effect early vascular alteration precede clinical event .</brief_summary>
	<brief_title>Mesoglycan , Vascular Reactivity Metabolic Syndrome</brief_title>
	<detailed_description>The subject enrol double blind randomized way , accord 2 : 1 ratio , intramuscular treatment mesoglycan placebo . Patients perform study Flow Mediated Dilation ( FMD ) accord follow scheme : - FMD baseline - FMD 2 hour administration 2 vial mesoglycan placebo intramuscularly - FMD 6 hour intramuscular administration . Nextly , patient treat mesoglycan vial placebo vial continue therapy assume mesoglycan placebo , per o , bi die , 90 day . At end period oral therapy ( mesoglycan placebo 2 : 1 ratio ) , patient perform FMD . The patient take specific therapy ( eg antihypertensive drug ) Placebo administer addition standard therapy . The vascular reactivity evaluation adopt Flow Mediated Dilatation ( FMD ) . After period fast rest least 6 hour , study FMD perform use high-resolution ultrasound system , equip 7.5 Megahertz linear probe ECG monitoring . After rest period least 10 minute bed supine decubitus air-conditioned room , sensor place humeral artery , 3-5 cm elbow , hold position examination arm mechanically connect . They perform number longitudinal section measure internal diameter vessel , define distance top edge echo produce interface lumen anterior wall vessel top edge echo produce interface lumen rear wall vessel . The inner diameter vessel measure several time , R wave ECG , pc `` software '' calculate average value . The flow rate measure sample volume place center vase 60 ° angle ultrasound beam longitudinal axis vessel . The post-ischemic vasodilation induce use sphygmomanometer place forearm , distal elbow crease , keep inflated 250 mmHg 5 minute . The flow rate , always correction angle 60 ° , record immediately desufflation ; diameter brachial artery , measure several time desufflation ( 60-90 second ) . Nextly , FMD calculate percentage difference maximum diameter post-ischemic reach mean diameter base vessel .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Titanium dioxide</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>3 follow criterion National Cholesterol Education Program ( NCEP ) Expert Panel Detection , Evaluation , Treatment High Blood Cholesterol Adults ( Adult Treatment Panel III ) : Increased abdominal circumference ≥102 cm man , ≥88 cm woman Triglycerides ≥150 mg / dL HDLcholesterol &lt; 40 mg / dL men , &lt; 50 mg / dL woman Systolic blood pressure &gt; 130 mm Hg diastolic blood pressure &gt; 85 mm Hg Blood glucose &gt; 100 mg / dL Indication cardiac surgery surgery perform less 3 month Under age 18 year Age great 65 year Inability perform periodic inspection Presence malignancy serious heart disease . Hemorrhagic diathesis disease . Hypersensitivity mesoglycan , heparin heparinoids . Type 1 diabetes type 2 Pregnancy / breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Mesoglycan</keyword>
	<keyword>Metabolic Syndrome</keyword>
	<keyword>Flow Mediated Dilation</keyword>
</DOC>